Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era

International Journal of Hematology

Volumn 93, Issue 2, 2011, Pages 186-191

  Muramatsu, Hideki ^a   Takahashi, Yoshiyuki ^a   Sakaguchi, Hirotoshi ^b   Shimada, Akira ^a   Nishio, Nobuhiro ^a   Hama, Asahito ^a   Doisaki, Sayoko ^a   Yagasaki, Hiroshi ^a   Matsumoto, Kimikazu ^b   Kato, Koji ^b   Kojima, Seiji ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

Author keywords

Chronic myeloid leukemia; Imatinib mesylate; Stem cell transplantation

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; HYDROXYUREA; IMATINIB; LYMPHOCYTE ANTIBODY; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; RANIMUSTINE; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY;

ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTHRALGIA; ARTICLE; BLAST CELL CRISIS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG RESPONSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; NEUTROPENIA; PANCYTOPENIA; PATIENT COMPLIANCE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; THROMBOCYTOPENIA; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79952251630     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0764-9     Document Type: Article

References (22)

1. AJ Altman 1988 Chronic leukemias of childhood Pediatr Clin North Am 35 765 787 1:STN:280:DyaL1czjsFCnsw%3D%3D 3047653
2. S Kojima J Yoshida S Yoshikawa H Iwamura T Tonouchi J Mimaya 1987 Philadelphia chromosome positive chronic myelocytic leukemia in children Acta Haematol Jpn. 50 819 827 1:STN:280:DyaL1c%2FntlSjuw%3D%3D
3. K Cwynarski IA Roberts S Iacobelli, et al. 2003 Stem cell transplantation for chronic myeloid leukemia in children Blood 102 1224 1231 1:CAS:528:DC%2BD3sXmsFWksb4%3D 10.1182/blood-2002-12-3637 12714525 (Pubitemid 36988026)
4. F Millot H Esperou P Bordigoni, et al. 2003 Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) Bone Marrow Transplant 32 993 999 1:STN:280:DC%2BD3srhs1KmsQ%3D%3D 10.1038/sj.bmt.1704255 14595387 (Pubitemid 37461535)
5. U Creutzig J Ritter M Zimmermann T Klingebiel 1996 Prognosis of children with chronic myeloid leukemia: a retrospective analysis of 75 patients Klin Padiatr. 208 236 241 1:STN:280:DyaK28znt12msQ%3D%3D 10.1055/s-2008-1046479 8926689 (Pubitemid 26246756)
6. DJ Weisdorf C Anasetti JH Antin, et al. 2002 Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation Blood 99 1971 1977 1:CAS:528:DC%2BD38XitF2nt7g%3D 10.1182/blood.V99.6.1971 11877268 (Pubitemid 34525477)
7. H Muramatsu S Kojima A Yoshimi, et al. 2010 Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: the Japan Marrow Donor Program Biol Blood Marrow Transplant. 16 231 238 10.1016/j.bbmt.2009.09.022 19800016
8. BJ Druker M Talpaz DJ Resta, et al. 2001 Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 1031 1037 1:CAS:528:DC%2BD3MXivFGnu70%3D 10.1056/ NEJM200104053441401 11287972 (Pubitemid 32267972)
9. TP Hughes J Kaeda S Branford, et al. 2003 Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 1423 1432 1:CAS:528: DC%2BD3sXotVGgs7s%3D 10.1056/NEJMoa030513 14534335 (Pubitemid 37211057)
10. MA Champagne R Capdeville M Krailo, et al. 2004 Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study Blood 104 2655 2660 1:CAS:528:DC%2BD2cXpslKjs7Y%3D 10.1182/blood-2003-09-3032 15231574 (Pubitemid 39434944)
11. F Millot J Guilhot B Nelken, et al. 2006 Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation Leukemia. 20 187 192 1:CAS:528:DC%2BD28Xmsl2qtQ%3D%3D 10.1038/sj.leu.2404051 16341042 (Pubitemid 43148651)
12. B Speck MM Bortin R Champlin, et al. 1984 Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia Lancet 1 665 668 1:STN:280:DyaL2c7ktVyjsg%3D%3D 10.1016/S0140-6736(84)92179-2 6142357 (Pubitemid 14169489)
13. M Baccarani G Saglio J Goldman, et al. 2006 Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 108 1809 1820 1:CAS:528: DC%2BD28Xpsl2isrc%3D 10.1182/blood-2006-02-005686 16709930 (Pubitemid 44394987)
14. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. 2009. http://ctepcancergov/protocolDevelopment/electronic-applications/ctchtm#ctc-40.
15. A Gratwohl R Brand J Apperley, et al. 2006 Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Haematologica 91 513 521 16533723
16. BJ Druker F Guilhot SG O'Brien, et al. 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2408 2417 1:CAS:528:DC%2BD28Xht12ntrzM 10.1056/NEJMoa062867 17151364 (Pubitemid 44903745)
17. RA Larson BJ Druker F Guilhot, et al. 2008 Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study Blood 111 4022 4028 1:CAS:528:DC%2BD1cXkvFeisrg%3D 10.1182/blood-2007-10-116475 18256322
18. S Picard K Titier G Etienne, et al. 2007 Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia Blood 109 3496 3499 1:CAS:528: DC%2BD2sXksFWhsrY%3D 10.1182/blood-2006-07-036012 17192396 (Pubitemid 46572540)
19. P Rousselot F Huguet D Rea, et al. 2007 Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years Blood 109 58 60 1:CAS:528:DC%2BD2sXivVyrtL4%3D 10.1182/blood-2006-03-011239 16973963 (Pubitemid 46053043)
20. S Guastafierro U Falcone M Celentano M Coppola MG Ferrara A Sica 2009 Is it possible to discontinue imatinib mesylate therapy in chronic myeloid leukemia patients with undetectable BCR/ABL? A case report and a review of the literature Leuk Res. 33 1079 1081 1:CAS:528:DC%2BD1MXmtVWgu7Y%3D 10.1016/j.leukres.2008.11.027 19167064
21. T Kiguchi T Tauchi Y Ito K Miyazawa Y Kimura K Ohyashiki 2009 Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase Leuk Res. 33 506 508 10.1016/j.leukres.2008.04.018 18533259
22. T Kimoto M Inoue K Kawa 2009 Growth deceleration in a girl treated with imatinib Int J Hematol 89 251 252 10.1007/s12185-008-0251-8 19152100